MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer
MSD has reported that the randomised Phase III KEYNOTE-B96 trial of Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), with or without bevacizumab,…
News
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy
Nuvig Therapeutics begins dosing in trial of NVG-2089 for CIDP
Examining shifts in clinical trial outsourcing
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug
GSK to spend $2bn on Phase III liver disease drug acquisition
